NATCO launches anticoagulant drug Rivaroxaban in India

Written by Ruchika Sharma Published On 2020-12-18T12:00:51+05:30 | Updated On 18 Oct 2023 5:28 PM IST

NATCO launches anticoagulant drug Rivaroxaban in India

Hyderabad: Natco Pharma Limited has recently announced the launch of Rivaroxaban molecule, under brand RPIGAT.

Rivaroxaban is an anticoagulant medication used to treat and prevent blood clots.

Rivaroxaban is currently sold by Bayer under brand name of Xarelto, in the Indian market.

"After successful previous launches of DABIGAT (Dabigatran) and APIGAT (Apixaban) by NATCO, this latest Rivaroxaban NOAC (Novel oral anti-coagulant) is in line with our Company's mission of affordable medicines accessible to all," the release stated.

NATCO has launched RPIGAT in four strengths- 20 mg, 15 mg, 10 mg and 2.5 mg. The 20 mg strength is priced at an MRP of INR 14.0 per tablet.

Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.

The Company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.

Read also: Natco Pharma net profit rises 73 percent to Rs 204 crore in Q2

natco pharmanatco pharma newsrivaroxabanrpigatblood clotanticoagulant drug

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751